Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what they are learning in this area.

[powerpress]

"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes what researchers are learning about these drugs still in early development. February 2014.

[powerpress]

Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and excitement for what the future may hold. February 2014.

[powerpress]

A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.

[powerpress]

Drs. Nasser Hanna and Melissa Johnson discuss developments in Immunotherapy since ASCO 2013.

[powerpress]

Drs. Nasser Hanna and Melissa Johnson discuss new trial evidence for the use of adjuvant Erlotinib for early-stage lung cancer.

[powerpress]

Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.

[powerpress]

The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.

[powerpress]

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

[powerpress]

The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.

[powerpress]